| Moon O Kwoun, MD | |
|
1493 Cambridge St, Cambridge, MA 02139-1047 | |
| (617) 665-2555 | |
| Not Available |
| Full Name | Moon O Kwoun |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 32 Years |
| Location | 1493 Cambridge St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205883956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | 156583 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cambridge Health Alliance | Cambridge, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cambridge Public Health Commission | 8921910894 | 536 |
News Archive
Modern Healthcare: Funding to help doctors and hospitals buy electronic medical records could begin to flow through the Medicare program as early as May 2011, a Centers for Medicare and Medicaid Services official said Wednesday. But, the final shape of the program remains unclear as CMS works to implement 800 pages of new regulations. "We're now working toward actually making all of this a reality, and we have less than six months to do it," the official said (Conn, 7/28).
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
For many states, 2011 is the most trying budget year of a fiscal crisis now in its fourth year. Revenues generally remain lower than what they used to be; widespread joblessness is putting unprecedented strains on safety-net programs like Medicaid; and all this is happening as federal stimulus money runs out.
Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.
› Verified 9 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
Modern Healthcare: Funding to help doctors and hospitals buy electronic medical records could begin to flow through the Medicare program as early as May 2011, a Centers for Medicare and Medicaid Services official said Wednesday. But, the final shape of the program remains unclear as CMS works to implement 800 pages of new regulations. "We're now working toward actually making all of this a reality, and we have less than six months to do it," the official said (Conn, 7/28).
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
For many states, 2011 is the most trying budget year of a fiscal crisis now in its fourth year. Revenues generally remain lower than what they used to be; widespread joblessness is putting unprecedented strains on safety-net programs like Medicaid; and all this is happening as federal stimulus money runs out.
Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Moon O Kwoun, MD 51 Common St, Belmont, MA 02478-3022 Ph: (617) 665-2555 | Moon O Kwoun, MD 1493 Cambridge St, Cambridge, MA 02139-1047 Ph: (617) 665-2555 |
News Archive
Modern Healthcare: Funding to help doctors and hospitals buy electronic medical records could begin to flow through the Medicare program as early as May 2011, a Centers for Medicare and Medicaid Services official said Wednesday. But, the final shape of the program remains unclear as CMS works to implement 800 pages of new regulations. "We're now working toward actually making all of this a reality, and we have less than six months to do it," the official said (Conn, 7/28).
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
For many states, 2011 is the most trying budget year of a fiscal crisis now in its fourth year. Revenues generally remain lower than what they used to be; widespread joblessness is putting unprecedented strains on safety-net programs like Medicaid; and all this is happening as federal stimulus money runs out.
Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.
› Verified 9 days ago
Karen L Ahlert, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Mount Auburn St, Suite 407, Cambridge, MA 02138 Phone: 617-868-7456 Fax: 617-868-9243 | |
Dr. Ronald Martin Weintraub, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1943 Cambridge St, Cambridge, MA 02139 Phone: 617-665-3194 Fax: 617-665-3577 | |
David I Becker, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cha - Surgery - Cambridge Campus, Cambridge, MA 02139 Phone: 617-665-2555 Fax: 617-665-3598 | |
Chantel Noelle Hile, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Mount Auburn St, Suite 407, Cambridge, MA 02138 Phone: 617-868-7456 Fax: 617-868-9243 | |
Dr. Aram Nazareth Demirjian, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Mount Auburn St Ste 407, Cambridge, MA 02138 Phone: 617-868-7456 Fax: 617-868-9243 | |
Dr. Ralph Wesley Vosburg, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 781-314-7600 |